Download MendeleyDevelopment of a covalent inhibitor of gut bacterial bile salt hydrolases.
Adhikari, A.A., Seegar, T.C.M., Ficarro, S.B., McCurry, M.D., Ramachandran, D., Yao, L., Chaudhari, S.N., Ndousse-Fetter, S., Banks, A.S., Marto, J.A., Blacklow, S.C., Devlin, A.S.(2020) Nat Chem Biol 16: 318-326
- PubMed: 32042200
- DOI: https://doi.org/10.1038/s41589-020-0467-3
- Primary Citation of Related Structures:
6UFY, 6UH4 - PubMed Abstract:
Bile salt hydrolase (BSH) enzymes are widely expressed by human gut bacteria and catalyze the gateway reaction leading to secondary bile acid formation. Bile acids regulate key metabolic and immune processes by binding to host receptors. There is an unmet need for a potent tool to inhibit BSHs across all gut bacteria to study the effects of bile acids on host physiology. Here, we report the development of a covalent pan-inhibitor of gut bacterial BSHs. From a rationally designed candidate library, we identified a lead compound bearing an alpha-fluoromethyl ketone warhead that modifies BSH at the catalytic cysteine residue. This inhibitor abolished BSH activity in conventional mouse feces. Mice gavaged with a single dose of this compound displayed decreased BSH activity and decreased deconjugated bile acid levels in feces. Our studies demonstrate the potential of a covalent BSH inhibitor to modulate bile acid composition in vivo.
Organizational Affiliation:
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
